Affini-T Therapeutics Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs
Multi-year research collaboration with Memorial Sloan Kettering Cancer Center (MSK) aims to propel future innovation for patients with solid tumors MSK’s Christopher A. Klebanoff, M.D., to serve Affini-T as Scientific Co-founder and Advisor BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced … [Read more…]
